Möchten Sie immer auf dem neuesten Stand bleiben?

–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...

-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive data...

GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction- -A...

GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need   Ad hoc...

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia–   GENEVA, Switzerland and BOSTON – July 2,...